A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia (NCT06843590)
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance-3)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to measure the safety and decrease in daytime sleepiness in subjects with Idiopathic Hypersomnia when taking ALKS 2680 tablets compared with placebo tablets
Who can join: Review the eligibility criteria below.
Location: Alkermes Investigator Site — Cullman, Alabama
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (50 Sites)
Showing the first 25 of 50 sites.
- Alkermes Investigator Site — Cullman, Alabama
- Alkermes Investigator Site — Phoenix, Arizona
- Alkermes Investigator Site — Little Rock, Arkansas
- Alkermes Investigator Site — Los Angeles, California
- Alkermes Investigator Site — Redwood City, California
- Alkermes Investigator Site — San Francisco, California
- Alkermes Investigational Site — Boulder, Colorado
- Alkermes Investigator Site — Colorado Springs, Colorado
- Alkermes Investigator Site — Brandon, Florida
- Alkermes Investigator Site — Miami, Florida
- Alkermes Investigator Site — Winter Park, Florida
- Alkermes Investigator Site — Atlanta, Georgia
- Alkermes Investigator Site — Macon, Georgia
- Alkermes Investigator Site — Stockbridge, Georgia
- Alkermes Investigator Site — Peoria, Illinois
- Alkermes Investigator Site — Kansas City, Kansas
- Alkermes Investigational Site — Boston, Massachusetts
- Alkermes Investigator Site — Lansing, Michigan
- Alkermes Investigator Site — Lincoln, Nebraska
- Alkermes Investigator Site — Middletown, New Jersey
- Alkermes Investigator Site — Denver, North Carolina
- Alkermes Investigator Site — Huntersville, North Carolina
- Alkermes Investigator Site — Canton, Ohio
- Alkermes Investigator Site — Cincinnati, Ohio
- Alkermes Investigator Site — Cleveland, Ohio
📞 Contact the Study Coordinator
Phone: (888) 235-8008
Email: clinicaltrials@alkermes.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Idiopathic Hypersomnia
- A Study of TAK-360 in Adults With Idiopathic Hypersomnia — Redwood City, California
- A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia — Brandon, Florida
- A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH) — Birmingham, Alabama
- Low Sodium Oxybate in Patients With Idiopathic Hypersomnia — Phoenix, Arizona
Explore by condition: All Idiopathic Hypersomnia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.